PD-1 Inhibitors +Venetoclax+CAG Regimens in R/R T-ALL

Más betegség

• Patients with refractory/relapsed T-ALL who are not suitable for or whose economic conditions restrict the use of PD-1 and venetoclax for treatment;
• Diseases that may limit patients' participation in this trial due to abnormal functions of organs such as the heart, lungs, liver, and kidneys (such as advanced infections, uncontrolled diabetes, severe heart failure or angina pectoris, active pulmonary tuberculosis, asthma, COPD, bronchiectasis, severe renal insufficiency, etc.);
• There has been a history of other malignant tumors within the past five years;
• Known HIV infection, active hepatitis B virus (HbsAg positive and HBV-DNA higher than the upper limit of the detection value) or active hepatitis C virus (anti-HCV antibody positive or HCV RNA positive) infection;

Életkor

• Patients under 18 years old.

Egyéb

• Inability to understand or comply with the research protocol;

• Age \>=18 years old;
• Met the T-ALL diagnosis before enrollment (for specific diagnostic criteria, see the attachment);
• Refractory T-ALL (newly diagnosed T-ALL that fails to achieve remission after treatment with one standard regimen) or recurrent T-ALL (bone marrow blasts exceed 5% again after remission, and the morphology and immunophenotype of leukemia cells are consistent with T-ALL);
• The performance status score of the Eastern Cooperative Oncology Group (ECOG) in the United States ranges from 0 to 2 points.
• Expected survival period \>=3 months;
• During the screening period, there were no organ function abnormalities that restricted the use of this scheme.
• Understand this study and sign the informed consent form.